The EasySep™ Mouse Biotin Positive Selection Kit II is designed to isolate cells that are labeled with biotinylated antibodies. Desired cells are targeted with antibody complexes recognizing biotin and dextran-coated magnetic particles. Labeled cells are separated using an EasySep™ magnet without the use of columns. Cells of interest remain in the tube while unwanted cells are poured off.
This product replaces the EasySep™ Mouse Biotin Positive Selection Kit (Catalog #18556).
For highly purified particle-free cells, we recommend the EasySep™ Release Mouse Biotin Positive Selection Kit (Catalog #17655).
This product replaces the EasySep™ Mouse Biotin Positive Selection Kit (Catalog #18556).
For highly purified particle-free cells, we recommend the EasySep™ Release Mouse Biotin Positive Selection Kit (Catalog #17655).
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
未找到
Resources and Publications
Educational Materials (7)
Publications (1)
Blocking CCL8-CCR8-Mediated Early Allograft Inflammation Improves Kidney Transplant Function. Journal of the American Society of Nephrology : JASN 2022 oct
Abstract
BACKGROUND In kidney transplantation, early allograft inflammation impairs long-term allograft function. However, precise mediators of early kidney allograft inflammation are unclear, making it challenging to design therapeutic interventions. METHODS We used an allogeneic murine kidney transplant model in which CD45.2 BALB/c kidneys were transplanted to CD45.1 C57BL/6 recipients. RESULTS Donor kidney resident macrophages within the allograft expanded rapidly in the first 3 days. During this period, they were also induced to express a high level of Ccl8, which, in turn, promoted recipient monocyte graft infiltration, their differentiation to resident macrophages, and subsequent expression of Ccl8. Enhanced graft infiltration of recipient CCR8+ T cells followed, including CD4, CD8, and ?? T cells. Consequently, blocking CCL8-CCR8 or depleting donor kidney resident macrophages significantly inhibits early allograft immune cell infiltration and promotes superior short-term allograft function. CONCLUSIONS Targeting the CCL8-CCR8 axis is a promising measure to reduce early kidney allograft inflammation.
Legal Statement: Users of this kit should ensure that they are entitled to use the antibody of interest. STEMCELL Technologies Inc. is not responsible for patent infringements or violations that may occur when using this product. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
